Boyds, MD, United States of America

Herren Wu

USPTO Granted Patents = 50 

 

 

Average Co-Inventor Count = 3.9

ph-index = 20

Forward Citations = 943(Granted Patents)

Forward Citations (Not Self Cited) = 882(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Germantown, MD (US) (2007 - 2009)
  • San Diego, CA (US) (2001 - 2010)
  • Houston, TX (US) (2003 - 2010)
  • Boyds, MD (US) (2007 - 2019)
  • Gaithersburg, MD (US) (2013 - 2019)

Company Filing History:


Years Active: 2001-2019

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Angiopoietin-2 Antibodies
Anti-IFNAR1 Antibodies
Humanized Anti-CD19 Antibodies
Protein Scaffolds
High Affinity Antibodies
Recombinant IL-9 Antibodies
Eph Receptor Fc Variants
Ultra High Affinity Neutralizing Antibodies
Anti-Factor D Antibodies
Antibody Effector Function Modulation
Membrane IgE Specific Antibodies
Nucleic Acids Encoding Antibodies
50 patents (USPTO):Explore Patents

Title: Herren Wu: Innovating Antibody Therapeutics from Boyds, MD

Introduction

Herren Wu, an accomplished inventor and innovator based in Boyds, Maryland, holds an impressive portfolio of 50 patents. His work primarily focuses on the development of advanced antibody therapeutics, demonstrating his commitment to enhancing medical treatments and therapies.

Latest Patents

Among Herren Wu's latest contributions to the field are two notable patents. The first, "Stabilized Angiopoietin-2 Antibodies and Uses Thereof," describes stabilized antibodies targeting Angiopoietin-2, along with nucleic acid and amino acid sequences, and hybridomas or other cell lines for expressing these antibodies. The second patent, "Anti-IFNAR1 Antibodies with Reduced Fc Ligand Affinity," provides a novel class of anti-IFNAR1 antibodies with reduced affinity for Fc receptors, including methods for their production and application.

Career Highlights

Herren Wu has made significant strides in his career, having worked with prestigious biopharmaceutical companies such as MedImmune Limited and Genentech, Inc. His tenure at these organizations has allowed him to contribute crucial advancements in therapeutic antibody development.

Collaborations

Throughout his career, Herren has collaborated with esteemed coworkers including William D. Huse and Peter Kiener. These partnerships have further enhanced his research and innovation in antibody therapeutics, driving the boundaries of science to improve patient outcomes.

Conclusion

Herren Wu's extensive patent portfolio and collaborations highlight his vital role in the biotech industry. His innovations in antibody therapeutics are paving the way for more effective medical solutions, demonstrating the impact one inventor can have on healthcare. Through his dedication and expertise, Herren continues to shape the future of therapeutic treatments for various diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…